NATIONWIDE RECRUITMENT: PEDIATRIC BIPOLAR DISORDER RESEARCH STUDY; NIMH: CLINICAL TRIAL OF RILUZOLE IN PEDIATRIC BIPOLAR DISORDER

Pin It

This study is testing the effectiveness of riluzole versus placebo for decreasing anxiety in children with pediatric bipolar disorder. Children and youth with bipolar disorder display episodic elevated mood and associated symptoms of decreased need for sleep, increased goal-directed behavior, and increased self-esteem/grandiosity. Children ages 9 to 17 with bipolar disorder may be eligible to participate in this 12- to 15-week inpatient or outpatient study. This study has four phases. During Phase I, participants are gradually withdrawn from all current psychotropic medications. Phase II is a one-week medication-free period. During Phase III, which lasts two weeks, participants are randomly assigned to receive either riluzole or placebo (a sugar pill). Phase IV lasts for 6 weeks. During this phase, participants continue riluzole or placebo. At the end of the study, those who received placebo have the opportunity to receive riluzole. All procedures and medications associated with the research are provided at no cost to participants, and assistance with transportation and lodging expenses is available. Schooling will be provided while on the inpatient unit or in day treatment. To find out more information, call (301) 496-8381 or email bipolarkids@mail.nih.gov

For more information on research conducted by the NIMH in Bethesda, MD, visit: http://patientinfo.nimh.nih.gov

Speak Your Mind

*